Funding

California-Based AusperBio Raises $120M in Series C Funding

Aug 29, 2026 | By Devin Jacobs

SUMMARY

AusperBio raised $120M in Series C funding.
The funding will support hepatitis B treatments.
AusperBio develops targeted therapies for chronic hepatitis B.

AusperBio, a San Francisco, CA-based biopharmaceutical company focused on developing targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B (CHB) and other diseases, has raised $120 million in a Series C financing round, led by a strategic investor, bringing the total amount to $360M.

The round also saw participation from RA Capital Management, HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, and CDH Investments.

The company will use the capital to advance treatments for chronic hepatitis B (CHB) and expand its pipeline.

Funding Snapshot

Metric	Details
Fundraise Amount	$120 million
Funding Stage	Series C
Total Funding	$360 million
Company	AusperBio
Sector	Biopharmaceuticals
Headquarters	San Francisco, California

RECOMMENDED FOR YOU

Funding

[Funding alert] CA-based Rune Labs Secures $12M in a Strategic Funding

Devin Jacobs

Jan 12, 2024

Funding

[Funding News] Sedric AI Raises $18.5 Million in Series A Funding

Team SR

Sep 6, 2024

Startup News

Genesco Names Jonathan Collins Chief Financial Officer

Devin Jacobs

Jun 29, 2026

About AusperBio

Founded in 2024 by Guofeng Cheng and Chris Yang, AusperBio develops oligonucleotide therapeutics, a type of medicine designed to target specific genetic material involved in disease.

The company is initially focused on developing treatments that could provide a functional cure for chronic hepatitis B.

Core offerings include:

AHB-137 ASO therapy
AHB-171 HBV siRNA therapy
Med-Oligo™ ASO platform
Au-HALO™ targeted delivery platform

Core Technologies / Products / Services

Capability/Product	Application/Use Case
AHB-137	Investigational therapy for chronic hepatitis B
AHB-171	HBV siRNA candidate
Med-Oligo™	Oligonucleotide therapeutic platform
Au-HALO™	Targeted drug delivery technology

Leadership Comments

"This financing represents an important inflection point for AusperBio as we advance AHB-137 toward potential commercialization while developing next-generation therapies for CHB," said Dr. Guofeng Cheng, co-founder and CEO of AusperBio. "We are grateful for the continued confidence of our existing investors and pleased to welcome RA Capital to AusperBio.

Dr. Chris Yang, co-founder and CSO of AusperBio, added, "AHB-137 has demonstrated promising clinical activity in patients and has the potential to serve as a backbone therapy for functional cure of CHB. Our Med-Oligo™ ASO, Au-HALO™ targeted delivery and siRNA discovery platforms enable complementary approaches designed to achieve deeper and more durable antiviral responses.